Mirvetuximab-MMAE (ADC)
Mirvetuximab-MMAE is an ADC consisting of an FRA-directed antibody and Monomethyl auristatin E (MMAE) used for the study of ovarian cancer.
Product Specifications
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Form
Liquid
Notes
For research use only. Not suitable for clinical or therapeutic use.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
C2548-84Z5-AP 100 µL
CD154, soluble (CD40 Ligand, CD40-L, CD40L, CD40LG, gp39, hCD40L, HIGM1, IGM, IMD3, T-BAM, T-cell Antigen GP39, TNF-related Activation Protein, TRAP, Tumor Necrosis Factor Ligand Superfamily Member 5, TNF Ligand Superfamily Member 5, TNFSF5) (AP) discontinued
Ask
View Details